Last reviewed · How we verify
Fluoxetine (prozac)
Fluoxetine (prozac) is a Selective serotonin reuptake inhibitor (SSRI) Small molecule drug developed by Neuropharm. It is currently FDA-approved for Major depressive disorder, Obsessive-compulsive disorder, Panic disorder.
Fluoxetine selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain.
Fluoxetine selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain. Used for Major depressive disorder, Obsessive-compulsive disorder, Panic disorder.
At a glance
| Generic name | Fluoxetine (prozac) |
|---|---|
| Sponsor | Neuropharm |
| Drug class | Selective serotonin reuptake inhibitor (SSRI) |
| Target | Serotonin transporter (SERT) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that blocks the serotonin transporter protein, preventing the reabsorption of serotonin from the synaptic cleft back into presynaptic neurons. This increases serotonin concentration in the synapse, enhancing neurotransmission and improving mood regulation. The drug has minimal effects on other neurotransmitter systems compared to older antidepressants.
Approved indications
- Major depressive disorder
- Obsessive-compulsive disorder
- Panic disorder
- Bulimia nervosa
- Premenstrual dysphoric disorder
Common side effects
- Nausea
- Headache
- Insomnia
- Somnolence
- Sexual dysfunction
- Tremor
- Diarrhea
- Dry mouth
Key clinical trials
- The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (PHASE4)
- Fluoxetine and Understanding Social Experiences (NA)
- Behavioral Activation and Medication Optimization In Older Adults Undergoing Cardiac Procedures (NA)
- National Pregnancy Registry for Psychiatric Medications
- Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus (DM) (EARLY_PHASE1)
- The Effects of Fluoxetine and/or DHEA (EARLY_PHASE1)
- Care Transition Intervention for Hospitalized Patients With Advanced Cancer (NA)
- Cellular Aging and Neurobiology of Depression Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluoxetine (prozac) CI brief — competitive landscape report
- Fluoxetine (prozac) updates RSS · CI watch RSS
- Neuropharm portfolio CI
Frequently asked questions about Fluoxetine (prozac)
What is Fluoxetine (prozac)?
How does Fluoxetine (prozac) work?
What is Fluoxetine (prozac) used for?
Who makes Fluoxetine (prozac)?
What drug class is Fluoxetine (prozac) in?
What development phase is Fluoxetine (prozac) in?
What are the side effects of Fluoxetine (prozac)?
What does Fluoxetine (prozac) target?
Related
- Drug class: All Selective serotonin reuptake inhibitor (SSRI) drugs
- Target: All drugs targeting Serotonin transporter (SERT)
- Manufacturer: Neuropharm — full pipeline
- Therapeutic area: All drugs in Psychiatry / Neurology
- Indication: Drugs for Major depressive disorder
- Indication: Drugs for Obsessive-compulsive disorder
- Indication: Drugs for Panic disorder
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing